A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients: Early Action Reduces Long-term Yield in Hidradenitis Suppurativa (EARLY HS 2)

The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.

Inclusion criteria:

• Patients with a documented diagnosis of HS (e.g., International Classification of Diseases, 10th Revision [ICD-10] code L73.2);
• Age ≥18 years at index date;
• Moderate-to-severe HS as per label;
• Initiation of secukinumab treatment on or after the first HS diagnosis date;
• And at least one follow-up assessment at 6 or 12 months after index date.

Exclusion criteria:

• Patients who had major HS-related surgery (Skin-tissue-sparing Excision with Electrosurgical Peeling [STEEP] or wide excision) in the 12 months prior to index date;
• Patients participating in interventional clinical trials at index date.

Other protocol-defined inclusion/exclusion criteria may apply.